Tag Archives: Global
By Clark Herman | Published: April 26, 2013
In a recent survey by Ipsos Healthcare, oncologists from the US, China, Brazil, and the EU Big 5, expressed strong dissatisfaction with the direction and pace of local healthcare initiatives. Conducted in February of this year, the survey indicates that a substantial portion of its 257 respondents—an average of 40% across these markets – are [...]
By William Looney | Published: January 30, 2013
Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day. Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the [...]
By Clark Herman | Published: January 17, 2013
Global consultancy Cegedim has released its latest survey on how and where big Pharma puts its promotional dollar. Pharmaceutical Promotional Spend: Global Trends reports that spending in emerging markets significantly increased last year, while Europe and US declined slightly. Although overall promotion spending remained flat worldwide at $90 billion, the US still accounts for the [...]
By Ben Comer | Published: October 1, 2012
US-based SciClone Pharmaceuticals has built its business around selling specialty drugs in China. Companies like Sanofi and Pfizer, despite their own in-country resources, have partnered with SciClone and are achieving better returns, according to SciClone CEO Friedhelm Blobel.
By Ben Comer | Published: July 12, 2012
The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?